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Introduction
The aging of population is an important social,
economic and political issue. It has been estimated
that in 2030, approximately 21% of the population
will be aged over 65 years; thus will further
increase the number of geriatric patients and health
demand(1).
In particular, to date, it has been estimated that
about half of outpatient visits made by general
practitioners in the elderly regards gastroenterologi-
cal-related problems. In elderly, Gastro-Esophageal
Reflux Disease (GERD), is very common among
gastrointestinal diseases, unusually more severe
than young patients frameworks. In the elderly, fre-
quently, GERD is under-diagnosed, usually because
of the chronic proton-pump inhibitors (PPIs) thera-
py prescribed as protection for iatrogenic drug dam-
ages, such as antiplatelet and nonsteroidal anti-
inflammatory drugs (NSAIDs)(2-4). 
GERD is a consequence of pathological reflux
of gastric and/or duodenal contents in the esopha-
gus, which can induce a spectrum of clinical condi-
tions ranging from simple symptomatic reflux to
esophageal mucosal injury (esophagitis) and even
complications such as stenosis and Barrett's esopha-
gus(5-9). 
The study of the different GERD framework
in elderly is complicated by several factors.
Esophageal sensitivity seems decrease with aging
and elderly patients usually underestimate and tol-
erate symptoms that the younger ones do not. The
coexistence of other diseases, such as chronic
obstructive pulmonary disease (COPD) and coro-
nary heart disease (CHD), may be confused or
exacerbated by GERD(10). 
Furthermore, a long-term therapy with drugs
such as calcium-antagonists and nitrates in elderly
patient with cardiac disease and/or high blood pres-
sure, facilitates the GERD onset, as these drugs
reduce lower esophageal sphincter (LES) muscle
tone and consequently determining incontinence.
Cholecystectomy, very frequent in elderly, especial-
ly women, is another possible risk factor for a con-
stant duodenal-gastric reflux, which can easily
spread to the esophagus. Generally, in elderly, most
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common symptoms are regurgitation, dysphagia,
chest pain and respiratory symptoms rather than
heartburn(11).
Using PubMed and Medline, we performed a
research using as keywords “GERD”, “elderly”,
“acid reflux disease”, “gastroesophageal reflux”,
“hiatal hernia”, “antacids”, “PPIs” and
“endoscopy”.
Epidemiology
The considerable clinical variability of GERD,
clearly evident in elderly patients, creates a lot of
difficulties in collecting accurate epidemiological
data. As regards prevalence data, studies about typi-
cal symptom of “heartburn” and endoscopic diag-
nosis of esophagitis have been performed(12,13).
General population complains of monthly
heartburn between 21% and 36%, and between 5%
and 7% of daily one. In a recent study performed on
559 elderly patients, 8% of males and 15% of
females had symptoms suggestive of gastro-
esophageal reflux at least once a week. Symptoms
reported at least once a month in 54% of men and
66% of women. In addition to reflux typical symp-
toms chest pain, dyspepsia, and respiratory symp-
toms were associated too(8,14,15).
A GERD risk factor is given by the increased
frequency of overweight or obesity both in general
population and in elderly one, for, at least, two rea-
sons: increased lipids intake raises acid secretion
and reduces the gastric emptying time; moreover,
increasing of abdominal pressure facilitates the
reflux(16-18). 
Locke et al. report that both atypical chest pain
and acid regurgitation, are present in 20% of elderly
patients (aged over 75 years old) at least once a
week, and in 59% at least once a month.
Esophagitis rate ranges between 1% and 22%, with
a higher frequency of mild grades compared to
severe or complicated ones(14).
It has been observed that 32-43% of patients
with GERD did not present endoscopic lesions,
while 50-60% of patients with typical symptoms
and 60% of patients with atypical symptoms had an
endoscopic diagnosis of esophagitis. Respiratory
symptoms were reported in 57% of patients with
esophagitis compared with 33% of those without
this last one(9,19).
In elderly patients subjected to endoscopy for
abdominal symptoms and/or anemia, esophagitis
was diagnosed with stage ranging from II to IV in
18% of cases; 29% did not have typical symptoms
of esophagitis and only 24% of patients with regur-
gitation had also esophagitis. Zhu et al. showed that
reflux disease and esophagitis incidence is higher in
symptomatic elderly patients compared to younger
ones (66% vs. 46.9%). Furthermore, patients with
reflux symptoms have worst esophageal injury
(esophagitis III/IV 20.8% vs. 3.4%)(13).
Moreover, in elderly is frequent hiatal hernia,
a GERD closely related condition.
As well as the GERD prevalence increases
with age, becoming particularly high after 50 years
old, so the incidence increases significantly (mean
age 55 years old) (Figure 1). Even esophagitis
severity increases significantly with aging, as it
reported in an endoscopic study in which 75% of
patients with esophagitis was represented by “six-
ties”. In this regard, a recent U.S. study has con-
firmed this trend showing an increase in hospital
admissions for esophagitis, esophageal ulcer and
stenosis (Figure 2)(11,20).
Figure 1: GERD incidence
Figure 2: Hospital admissions for esophagitis,
esophageal ulcer and stenosis
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GERD Complications are more common
among the elderly. In particular, the esophageal
stenosis and
Barrett’s esophagus reach their maximum fre-
quency between 50 and 70 years old. Prevalence of
esophageal stenosis in patients with esophagitis
ranges between 10% and 20%, while incidence is
estimated around 8%. Barrett's esophagus, charac-
terized by the presence of columnar epithelium
replacing normal squamous epithelium in the third
lower esophageal, is considered a pre-neoplastic
lesion, which neoplastic transformation risk is from
30 to 125 times higher than the normal epithelium;
adenocarcinoma onset within a Barrett’s esophagus
has a prevalence ranging between 8% and 15%,
with an average age around 60 years old(7,21,22).
Natural history
GERD natural history data were collected in
the last two decades with the introduction of diag-
nostic techniques such as esophageal manometry
and 24h pH-metry. GERD is a clinical syndrome
with a chronic-relapsing course, characterized by
low annual mortality (0.42/100.000); the main
causes of death are esophageal bleeding (52%) and
aspiration pneumonia (35%)(23,24). Decease, due to
these complications, is more frequent in patients
with severe concomitant diseases (neurological or
psychiatric disorders, heart disease, alcoholism,
asthma, chronic bronchitis, stroke), conditions often
found in elderly patients(25,26).
Therapy discontinuation usually results in
symptoms recurrence. A prospective study showed
that 70% of patients exhibit GERD symptoms with-
in three years after therapy suspension, and a pro-
longed remission of symptoms occurs only in a
minority of patients (30%). However, reduction or
disappearance of symptoms does not always coin-
cide with reflux disease disappearance: patients
tested 17-32 years after diagnosis, treated with
medical therapy, have shown that though 75% had
symptoms improvement, about 66% showed patho-
logical reflux signs (pH-metry positive, esophagitis,
Barrett’s esophagus)(27,28).
Most of the patients with a durable remission
changed lifestyle, took antacids as needed, but most
of all cycles of 4-8 weeks with anti-secretory drugs,
while in others is necessary a continuous control by
medication and in rare cases, non-responders to
therapy with high PPIs dose, an anti-reflux
surgery(29,30).
Physiopathology
GERD study in elderly must consider the phy-
siological changes of organs and systems due to
aging.
Although the old concept of “presby-esopha-
gus” (a condition characterized by reduced contrac-
tile capacity, LES incomplete relaxation and esop-
hageal dilatation) can now be considered passed, is
however undeniable that in elderly can be observed
several changes in esophageal motility. Recent stu-
dies have demonstrated that elderly exists:
• a reduced LES pressure;
• a delay in esophageal relaxation after swallo-
wing;
• a decrease in secondary esophageal peristal-
sis (propulsive waves induced by swallowing);
• an increase in tertiary peristalsis (propulsive
asynchronous waves)(31-33).
Recently, these changes have been related to
the presence of typical elderly comorbidities, such
as diabetes mellitus, neurological disorders and
polypharmacy, while healthy elderly show only
insignificant changes in esophageal motility than
younger people(34-36).
Pathogenesis of GERD is multifactorial
(Figure 3) but is mainly related to motility abnor-
mality, which results in a prolonged and repeated
contact of the esophageal mucosa with the gastric
contents and/or duodenal one(37,38).
The main pathophysiological event is repre-
sented by the insufficient functioning of the anti-
reflux barrier represented by LES and muscular
bundles of the diaphragm surrounding the esopha-
gus. LES tonic contraction is the main mechanism
to prevent the reflux, and manometric studies have
clearly shown that reflux episodes are linked with
Figure 3: GERD physiopathology
LES relaxations. These are mostly found in post-
prandial period and are favored by gastric disten-
sion, representing about 80% of all reflux episo-
des(39-41).
In elderly patients is frequent and clear the dif-
ficulty to maintain the upright position (especially
in the post-prandial period) because elderly patients
are often:
• bedridden for acute or sub-acute pathologies
(it is known that only a few days of bed rest in
elderly lead to GERD with esophagitis);
• affected by an immobilization syndrome
resulting from disabling neurological or neuro-vas-
cular disease; 
• carriers of severe kyphoscoliotic deforma-
tions of spinal column(42,43).
All these conditions increase the number and
duration of episodes of nocturnal reflux, with a
GERD enhancement, also due to a natural reduction
of esophageal clearance and saliva (alkaline) pro-
duction during sleep. In the elderly there is a hypo-
tonia-hypotrophy of diaphragm and gastro-phrenic
ligaments that, in addition with hiatal hernia, contri-
bute to determine LES incontinence(44).
The gastric acidity, nevertheless, plays a deci-
sive role on the appearance of symptoms and muco-
sal lesions, and it is established that increasing the
time during which pH remains <4, the damages
caused by reflux are worse(45).
More recently other factors have been studied
such as the epithelial barrier, the mechanisms of
cellular transport and local blood flow and has been
emphasized their role in maintaining the esophageal
epithelium integrity. Other factors contribute to pro-
mote reflux such as delayed gastric emptying,
which, however, does not seem to have different
patterns among the young and healthy elderly, redu-
ced tension of esophageal wall and a decreased
excitatory cholinergic innervation(6,47,49).
Multidrug therapy (Table 1), with drugs that
have as target the esophagus (Table 2), and comor-
bidities (Table 3) seem to play an important role in
elderly GERD genesis. These drugs can trigger or
enhance GERD mainly through two mechanisms:
1. direct injurious action on esophageal muco-
sa. In this category are included: NSAIDs, aspirin,
potassium salts, iron salts, steroids, bisphosphona-
tes. These drugs should be avoided or administered
with caution in elderly patients who have: a redu-
ced esophageal motility (leads to an increased time
of contact between the ingested capsule and esop-
hageal mucosa); a decreased resistance of esopha-
geal mucosa: several factors as salivary secretion,
production of salivary and esophageal EGF (epider-
mal growth factor) and esophageal prostaglandins
and sub-mucosal blood flow, are often deficient in
elderly patient; a difficulty in maintaining an
upright position.
2. reduction of LES pressure. In this category:
dopaminergic drugs, benzodiazepines, tricyclic
antidepressants, calcium channel blockers and
nitrates(35,48-51).
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Reduced pressure of LES Direct mucosal damage
Theophylline Tetracycline
Progesterone Quinidine
Anti-cholinergics Potassium salts
β-agonists Iron salts
Dopamine NSAIDs
Diazepam Bisphosphonates
Opioids
Calcium Channel Blockers
Nitrates
Table 1: Drugs that provoke direct or indirect alteration
of the esophagus.
Diuretics 68%
Anti-hypertensive 61%
Laxatives 59%
Inotropes, anti-arrhythmics, vasoactive 56%
Bronchodilators, mucolytics, analeptics 47%
NSAIDs, salicylates 46%
Sedatives, hypnotics 36%
Antacids, anti-ulcer drugs 29%
Anti-platelet 21%
Steroids 17%
Oral hypoglycaemic agents, insulin 15%
Other 43%
None 5%
Table 2: Main drugs taken by elderly patients.
Effects of aging on normal patterns of gastro-
esophageal reflux 
In a late study on 110 healthy subjects with a
mean age of 38 years, an increase, though modest,
of gastro-esophageal reflux in relation with age
was seen, more common in women than in men.
Furthermore, in older patients reflux was greater
in supine position with various episodes longer
than 5 minutes. However, the difference between
groups of patients has not been proved significant,
as more recently demonstrated by other authors. In
elderly patients with symptomatic GERD, has
been observed the existence of an higher acid
reflux compared to younger patients, both in ort-
hostatic or in supine position, to which also cor-
responds an higher frequency of severe esophagi-
tis (Figure 4).
Clinical manifestations
Heartburn and acid regurgitation are the symp-
toms commonly considered “typical” of GERD.
However, there is no symptoms complex that
may be considered pathognomonic. Furthermore,
GERD was properly represented as an iceberg,
whose submerged part represents the majority of
subjects with mild symptoms that rarely require
therapy, while the emerging part corresponds to the
smaller group of patients who, because of the seve-
rity of symptoms and/or lesions of esophageal
mucosa, contact the physician and need a treat-
ment(9). In the study performed by Raiha et al. a
group of 195 elderly patients subjected to gastroin-
testinal endoscopy for dyspeptic disorders, has been
proved that 18% had grade II-IV esophagitis.
Among these patients approximately half did not
complain heartburn, unlike studies performed in
younger ones in which this symptom was referred
in 80% and 90% of cases. Moreover, heartburn was
not correlated to the presence of GERD, unlike
regurgitation, dysphagia and respiratory symptoms.
Finally, a third of patients with esophagitis did not
complain symptoms related to GERD(20). In another
study, however, heartburn was the predominant
symptom among younger patients and elderly. In
the latter, nevertheless, regurgitation and dysphagia
were more frequent compared to the other group(52).
The absence of typical reflux symptoms could be
explained by the presence of an autonomic neuro-
pathy, which alters the severity and typology of
symptoms, justifying the frequency of asymptoma-
tic patients with complications such as stenosis,
Barrett's esophagus and characteristic respiratory
disorders of the elderly population affected by
GERD such as asthma, chronic cough, recurrent
pneumonia and interstitial pulmonary fibro-
sis(11,20,52,53). 
Among respiratory manifestations, asthma has
been the most studied. The possible pathogenic
mechanisms to be considered are the irritating
action of gastro-esophageal reflux on the respirato-
ry system or the presence of an esophageal-bron-
chial reflex vagus-mediated(19).
Farther, studying the respiratory function in
elderly patients with GERD using spirometry, it
was proved that among these subjects with patholo-
gical pH-metric patterns, were present restrictive
alterations. There are also frequent symptoms inclu-
ding hoarseness, chronic cough, chronic laryngitis,
vocal cord granulomas or larynx cancer.
Manometric studies have shown that LES pressure
is reduced during the night, exposing pharynx to the
damaging attack of gastro-esophageal reflux(16-18).
Even dysphagia, characterized by the sensa-
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Figure 4: Reflux in patients with symptomatic
GERD.
Disease Age <65 y.o. (%) Age >65 y.o. (%)
None 49.3 28.6
Cardiorespiratory 23.4 62.7
Vascular 8.7 18.9
Metabolic 16.1 21.5
Osteoarticular 27.9 45.8
Renal 14.5 24.5
Haepatic 19.6 27.3
Neuropsychiatric 6.2 18.4
Other 26.6 35.6
Table 3: GERD comorbidities
tion of arrest or by a difficult progression of food
along the esophagus, is a frequent symptom in
elderly affected with GERD, also not complicated,
in this case as an expression of a motility disorder,
but may also be the predominant symptom of esop-
hageal stenosis due to reflux or tumor.
Regurgitation, symptom that typically occurs after
meals, especially if in supine position, is the clini-
cal expression of LES incontinence. In elderly this
symptom is more common than heartburn which,
however, can be associated with(11,54).
Complications
As already mentioned, the most frequent com-
plications are represented by peptic stenosis and
Barrett's esophagus. pH-manometric studies, in
patients with Barrett’s esophagus, have documented
the presence of an excessive gastro-esophageal
reflux, especially in supine position, a strict LES
hypotonia and a reduced distal esophagus contracti-
lity. Diagnosis average age is around 60 years old,
more frequently in males and smokers
patients(7,8,55,56).
There are no specific symptoms, and often
patients have symptoms even mild or absent than
those with esophagitis, probably due to a decreased
acid-sensitivity of esophageal mucosa. There is
now a general consensus in considering Barrett's
esophagus a pre-neoplastic lesion, related to the
onset of adenocarcinoma, which have a prevalence
between 0.0% and 46.5% according to different
series considered. Massive bleeding is rare, can be
caused by ulcerative esophagitis and is usually trig-
gered by precipitating factors such as antiplatelet
agents and/or anticoagulants treatment. Conversely,
microcytic-hypochromic anemia is found in about
5% of patients with esophagitis and, above all, may
be the only clinical sign in elderly(9,21,57-59).
Diagnosis
GERD diagnosis is, usually, made by instru-
mental techniques; endoscopy and esophageal 24
hours pH-metry are the most used, because extre-
mely sensitive and specific.
Esophagogastroduodenoscopy (EGDS)
While in younger subjects aged around 50
years old, EGDS should not be considered a first-
level exam and is only performed if a symptomatic
patient does not take advantage by a standard cycle
of PPIs therapy, in elderly patients endoscopy must
be considered a first-level exam, especially if there
are alarm symptoms (e.g. weight loss, dysphagia,
anemia, etc.). EGDS execution is necessary because
symptomatology is often poorly represented and
neoplastic diseases of esophagus and/or of gastric
fundus, which initially may provoke symptoms
similar to those of GERD, must be excluded(9,54,60-63).
24h pH-metry
Monitoring esophageal pH can be useful for
GERD diagnosis and therapy, in particular for non-
esophageal manifestations and non-cardiac chest
pain. Is a valid method, fairly widespread, to quan-
tify esophageal acid exposure. This measurement
allowed to better understand the main characteristic
of GERD pathogenesis and treatment. Calculate the
percentage of total time spent below pH values of
4.0 in 24 hours (optimal discriminant value) and the
association with symptoms is essential to evaluate
atypical or sporadic disorders(53,64-67). 
Esophageal manometry
Esophageal manometry purpose is to assess
the cardia competence, to measure the mechanical
properties of LES, to study esophageal motility and
recording esophageal peristaltic activity, identifying
primary and secondary motor disorders related to
reflux. The stationary manometry, now disused, has
been superseded by the ambulatory 24 hours regis-
tration, which records the motility of esophageal
body, allowing the study of circadian motor events
and their correlation to physical activity, meals and
sleep(16-18).
Gastric scintigraphy
It has become the gold standard for the study
of gastric emptying. It is minimally invasive, well
accepted and with minimum radiation amount.
However, it is not quite common or standardized.
The lack of standardization and the probable hete-
rogeneity of populations studied, justify the diffe-
rent results reported by literature, although the
majority of studies seems to show a slow emptying
in the elderly(19,68,69).
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Treatment
GERD management in elderly patient should
consider some variables common among this
patients such as:
1) the presence of comorbidity that requires
specific therapies and create the problem of interac-
tions with drugs commonly used in GERD;
2) the possible reduction in compliance, for
physical or psychiatric disorders, as well as for the
possible complexity of dosages, reducing the effec-
tiveness of treatment;
3) the changes in drug detoxification related to
age(2,70).
Is important to remember that clinical studies
for the GERD evaluation, generally, are carried out
on a younger population. The therapeutic approa-
ches commonly used in clinical practice are, initial-
ly, a non-pharmacological measures, or rather
hygienic-dietary-behavioral, such as body weight
reduction, smoking cessation (it has been proved
that smoke reduces LES tone), elevation of the
headboard, abolition of certain foods and drugs and,
finally, in a few non-responders patients a surgical
intervention(2-4).
Treatment goals are, in the attack phase,
symptoms resolution and healing of injuries resul-
ting from changes in lifestyle, not always effective
and practicable, and from drug therapy. Another
objective is to consolidate the results obtained
maintaining remission of symptoms, healing of
injuries, and also preventing the complications(71).
Since the gastric acid reflux is one of the most
important factors in GERD pathogenesis, the con-
trol of acid secretion is the primary objective in this
area and several controlled clinical studies have
demonstrated the greater efficacy of PPIs compared
with H2 antagonists, drugs whose use is now limi-
ted to only those few patients who cannot tolerate
PPIs, or in association with the same PPI in poorly
responsive cases(2-4).
Other medications used are antacids, capable
of a temporary effect against acid secretion and pro-
kinetics, which allow to improve the esophageal
clearing, gastric emptying and increase the basal
tone of LES. When the disease is frequently relap-
sing, resistant to medical therapy and/or complica-
ted (severe esophagitis and/or stenosis), should be
considered the surgical approach, although, because
of the surgical risk of elderly patients, is rarely
practiced, even with the most modern and less inva-
sive laparoscopic techniques(2-4).
Medical therapy
Choosing the drug in geriatric patients is based
on the assessments of:
• effectiveness;
• tolerability and drug interactions;
• pharmacokinetic characteristics(2,70).
Antacids and mucus-protective
Antacids and mucous-protectors, such as
sucralfate and alginic acid, are usually taken as self-
medication before consulting the doctor, or prescri-
bed by a general practitioner if symptoms are mild.
In addition, they are sometimes used in combina-
tion with other drugs classes, in particular prokine-
tics. In literature, there are some comparative stu-
dies between alginate-antacids and placebo, which
show a limited role in controlling symptoms for
alginic acid(2-4,70,72).
H2-antagonists
As already said, in the therapy of esophagitis a
prominent role is played by drugs that reduce gas-
tric acid secretion(73,74). H2-antagonists have deter-
mined, in the ‘70s, a breakthrough in the treatment
of this disease, demonstrating a good effect both on
the improvement of symptoms and on the healing
of injuries, but with limited efficacy at standard
doses (used in peptic ulcer) as the healing rates
were not higher than 50%. Recent studies show that
only higher doses (1200-2400 mg) of H2-antago-
nists allow to improve the healing rate which,
however, is less consistent than their effect on the
symptoms.
Nevertheless, the administration of H2-antago-
nists in the elderly may cause various dose-depen-
dent side effects. The most important is central ner-
vous system involvement with a variety of symp-
toms, including: delirium, confusion, hallucina-
tions, depression, decreased libido and
Parkinsonism. The incidence of these effects increa-
ses particularly in patients with renal failure, so
these medicaments should be abandoned(2,3).
Proton Pump Inhibitors
Drugs that block the proton pump are certainly
the most effective in the GERD treatment; they
determine a marked and prolonged reduction of
gastric acidity and, consequently, reduce reflux(75-78).
The use of these molecules has also allowed
the healing of H2-antagonists refractory esophagi-
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tis. Historically, the first PPI introduced in clinical
practice was omeprazole, to which was subsequen-
tly added lansoprazole and pantoprazole, with an
almost equivalent effectiveness(79).
Although effectiveness of the various PPIs is
comparable, it seems appropriate to emphasize the
characteristics of pantoprazole and rabeprazole(80).
These molecules, in fact, besides having a more
rapid activation in a strongly acid pH and, probably,
a greater selectivity for the acid compartment of the
gastric parietal cell, are especially characterized by
a less interaction with the hepatic oxidative enzyme
systems, connected to cytochrome P450, which
make them more manageable, and secure specially
in elderly patients or in those with decreased hepa-
tic and renal function, without adjusting the dose
and, above all, with a lower risk of drug interac-
tions(81).
James et al. conducted a clinical trial compa-
ring H2-antagonists and omeprazole in elderly
patients with esophagitis. In these patients, omepra-
zole was approximately three times more effective
than H2-blockers (68% vs. 23%) on healing and
symptom resolution, even more than in younger
patients (57% vs. 29%)(82). 
The last molecule of PPIs group, esomeprazole,
isomeric omeprazole derivative, showed a more
powerful anti-secretory action with daily doses of 40
mg, which produced a significant benefit in the treat-
ment of erosive esophagitis and in pain chest, with
healing rates slightly higher than with other PPIs(2,83).
Prokinetic
Also these drugs are useful in GERD treatment,
considering the motor pathogenesis of this disease.
In fact, these molecules carry out their action on
esophagus, LES and stomach, increasing contraction
force (effect of esophageal clearing), enhancing LES
tone (improving the skills of the anti-reflux barrier)
and accelerating gastric emptying. The molecules
most frequently used are domperidone (anti-dopami-
nergic action), metoclopramide (central dopaminer-
gic antagonist), and levosulpiride, which due to the
several side effects has limited use. GERD natural
history shows that up to 80% of patients have a
relapse after acute healing, usually within six months
from treatment interruption. This determines the
need for a long-term therapy(28,84). 
Step-up and step-down therapy
Recently there has been many discussion about
the role of the molecules which should be used in
patients with suspected GERD and what should be
the most cost-effective approach. The therapy can be
started immediately using the more effective molecu-
les, then lowering the dosage or switching to a less
strong drug (step-down), sufficient to control the
symptoms; or start with those less powerful and, in
case of failure, continue with more powerful ones, to
obtain the disappearance of symptoms (step-up).
Both strategies have pros and cons, but there is no
doubt that the higher cost of more effective drugs
(PPIs), is quickly offset by better results both on
symptoms and on wound healing(2,83).
Surgical therapy
Is the alternative to medical therapy. The indi-
cations for GERD surgical treatment are very limi-
ted and are represented by medical therapy failure
and esophagitis development, complications such
as ulcers, stenosis and recurrent episodes of bron-
chial aspiration occurrence(58,81,85,86).
In absence of complications surgery is a viable
option if symptomatology interferes significantly
on the patient quality of life and if the latter refuses
a long term medical therapy. The mere presence of
hiatal sliding hernia is not an indication for surgery.
A randomized clinical trial has demonstrated the
greater efficacy of surgery (Nissen fundoplication)
compared to medical therapy with PPIs in male
patients with complicated GERD(87,88).
However, the indications for surgery are gene-
rally limited to young patients with a life expectan-
cy of many years, in which precisely surgical thera-
py can be an effective alternative to medical one.
The recent introduction of laparoscopic surgery in
GERD treatment, has expanded the number of sub-
jects on which can be carried out the intervention of
Nissen fundoplication(58,89).
The short-medium term clinical results are
comparable to those produced by traditional surge-
ry. Lately, 359 patients aged> 65 years study sho-
wed, after the intervention, a similar symptoms
improvement to that found among younger patients,
an equivalent morbidity and length of hospitaliza-
tion, emphasizing that the choice of surgical treat-
ment is no longer limited by age. Nevertheless we
must consider that elderly patients have a higher
surgical risk than younger ones(2,90,91).
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Endoscopic therapy
Medical and surgical therapy are undoubtedly
two cornerstones of GERD treatment, but to date
endoscopy offers new possibilities(92,93).
Three different approaches are available
today:
1) using an endoscope “sewing machine”.
With this technique could be performed sutures wit-
hin the cardia to form mucosal folds that contrast
reflux(94,95);
2) trough Radio-Frequency (NARROW proce-
dures), producing focal lesion in the cardia muscle
layer that hesitate in fibrosis with reflux reduc-
tion(95,96); 
3) injection of inert substances (polymers) into
the esophageal-gastric junction determines the crea-
tion of an anti-reflux barrier(95,97).
These procedures seem very promising, but
unfortunately are just in an experimental stage.
Before being widely adopted will be necessary to
make more accurate studies and a better standardi-
zation of procedures(95,98). 
Conclusions
In conclusion, GERD is a common condition
in the elderly, which often develops itself in an aty-
pical way, with more frequent and severe complica-
tions. As regards the pathophysiological mecha-
nisms in elderly patients compared to younger ones,
seem to have a specific role factors such as use of
drugs that reduce the LES tone or have direct detri-
mental action on the esophageal mucosa (in this
regard a special note, in women, the use of osteopo-
rosis medications, especially bisphosphonates, for
the well-known esophageal lesions that can cause),
presence of comorbidities (diabetes mellitus, neuro-
logical disorders), hiatal hernia, overweight, being
bedridden and probably duodenal-gastric reflux.
While the progressive age-related decrease of
hydrochloric acid (HCl) secretion, does not seem to
have an important protective role.
The diagnostic and therapeutic approach must
consider the psychological and physical changes
often present in the elderly. In absolute terms, treat-
ment effectiveness is very similar between young
and elderly. PPIs in the elderly, as in the young, are
considered the most effective molecules on symp-
toms and lesions of all grades. The choice of a spe-
cific molecule between PPIs has no influence in the
young, while in the elderly is required accounting
comorbidities and polypharmacy (interactions). 
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